Biopharmaceutical / Clinical-stage Drug Development
Strategic Profile
The lead drug candidate Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients. The company will soon file for approval in major economies including the United States and Europe, while also developing Fexapotide for early-stage, non-aggressive prostate cancer.
Cyborg Score Rationale
The company's stock was delisted from NASDAQ and resumed trading on OTCQB Venture Market in December 2024, representing a downgrade from prior listing. As of April 2025, stock price stood at $0.09 with market cap of $8.51M. Regulatory setbacks and limited financial runway present execution risks.
Top Insights
Lead drug Fexapotide Triflutate (NX-1207) completed Phase III clinical trials for BPH and Phase II trials for low-grade localized prostate cancer
December 2024 move to OTCQB listing from prior status, making stock eligible for proprietary broker-dealer quotations
Diversified pipeline includes NicAlert/TobacAlert tobacco detection tests and AlzheimAlert diagnostic assay for Alzheimer's disease diagnosis
Company founded in 1989 and headquartered in Nassau, Bahamas with R&D operations
Named Competitors
Avodart (Dutasteride) — 5-alpha reductase inhibitor for BPH
Proscar (Finasteride) — 5-alpha reductase inhibitor for BPH
Flomax (Tamsulosin) — Alpha blocker for BPH
Recent Developments
(December 2024) Stock resumed trading on OTCQB Venture Market under symbol NYMXF
(August 2024) Filed Annual Report with SEC
(July 2024) Marketing Authorization Application to Danish Medicines Agency failed to meet approval conditions
Open the full interactive Nymox Pharmaceutical Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.